Evacetrapib Treatment Does Not Lower CV Events Risk
Treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease.
(HealthDay News) — For patients with high-risk vascular disease, evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina, according to a study published in the New England Journal of Medicine.
A. Michael Lincoff, MD, from the Cleveland Clinic, and colleagues enrolled 12,092 patients with high-risk vascular disease. Participants were randomized to receive evacetrapib or matching placebo daily, as well as standard medical therapy.
The researchers observed a 31.1% decrease in the mean low-density lipoprotein cholesterol level with evacetrapib vs a 6.0% increase with placebo at 3 months; 133.2% and 1.6% increases were seen in the mean high-density lipoprotein cholesterol levels with evacetrapib and placebo, respectively. The trial was terminated early due to lack of efficacy after 1363 of the planned 1670 primary end-point events had occurred. A primary end point occurred in 12.9% and 12.8% of patients in the evacetrapib and placebo groups, respectively, after a median of 26 months (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P =.91)
"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures evacetrapib and funded the study.
- Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 18 May 2017. doi: 10.1056/NEJMoa1609581